Manufacturing matters, and six years ago, I said that one side effect from the pandemic is that mRNA technology, which had been lab-scale stuff, suddenly had dump-trucks full of money appearing to help them scale their manufacturing.
They apparently settled on the the sequences for the original covid vacs in a weekend. Going from that design to billions of doses is one of the hardest things to do, but once done, will persist. And it is ready to be deployed for the next hundred applications that we find for this.
Flu vaccines is an obvious application, since the prior egg-based manufacturing required about six months lead time and millions of eggs, but nobody wanted to invest in anything better.
[−]helsinkiandrew · 2026-07-02 Thu 03:38 UTC ·
link
> but nobody wanted to invest in anything better.
Not sure if you mean nobody wanted to develop mRNA flu vaccines, but at least Moderna and Pfizer are:
> They apparently settled on the the sequences for the original covid vacs in a weekend. Going from that design to billions of doses is one of the hardest things to do, but once done, will persist.
No no. They had a candidate for the vaccine. Scaling manufacturing is hard, sure, but the actual barrier was proving the candidate worked. We conducted (by far) the most time-efficient clinical trials in history to prove the vaccines were safe and effective.
Until that happened, we could not have known the candidate drug was actually correct.
They apparently settled on the the sequences for the original covid vacs in a weekend. Going from that design to billions of doses is one of the hardest things to do, but once done, will persist. And it is ready to be deployed for the next hundred applications that we find for this.
Flu vaccines is an obvious application, since the prior egg-based manufacturing required about six months lead time and millions of eggs, but nobody wanted to invest in anything better.
Not sure if you mean nobody wanted to develop mRNA flu vaccines, but at least Moderna and Pfizer are:
https://www.npr.org/2026/06/18/nx-s1-5863570/flu-vaccine-mrn...
No no. They had a candidate for the vaccine. Scaling manufacturing is hard, sure, but the actual barrier was proving the candidate worked. We conducted (by far) the most time-efficient clinical trials in history to prove the vaccines were safe and effective.
Until that happened, we could not have known the candidate drug was actually correct.